SPP1+ tumor-associated macrophages define a high-risk subgroup and inform personalized therapy in hepatocellular carcinoma
This study redefines the heterogeneity of TAMs beyond the M1/M2 paradigm, linking the TAMs trajectory genes to HCC patient stratification. <i>SPP1</i> blockade emerged as a strategy for counteracting immunosuppression, and cluster-specific therapies may optimize the management of HCC.
Authors
- Xinying Guo (ORCID: https://orcid.org/0000-0002-8428-5036)
- Linbin Lu (ORCID: https://orcid.org/0000-0003-3779-3457)
- Juan Luo (ORCID: https://orcid.org/0009-0001-2313-0065)
- Yamei Ye
- Jialin Chen (ORCID: https://orcid.org/0009-0009-9859-5535)
- Chen Li (ORCID: https://orcid.org/0000-0002-6895-2759)
- Xiong Chen (ORCID: https://orcid.org/0000-0001-5316-6512)
- Wei-Xuan Xu
Institutions
- Fujian Medical University (CN)
- Mengchao Hepatobiliary Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.3389/fonc.2025.1606195
- Citations
- 6
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 4.78
Funders
- Natural Science Foundation of Fujian Province
- Fujian Medical University